ArticleClinicoEconomics and outcomes research : CEOR2026
Cancer Medication Consumptions in Vietnam Between 2019 and 2023: An Analysis from the National Database.
Article in ClinicoEconomics and outcomes research : CEOR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study was conducted to analyse cancer medication consumption in Vietnam between 2019 and 2023. Materials and Methods: This was a cross-sectional study using data of cancer medication consumption that was publicly announced by Drug Administration of Vietnam (DAV) as a proxy. Data on expenditures and purchasing characteristics were extracted from every bidding package and contract implemented throughout the period. They afterwards were quantified and categorised by bidding technical groups, chemical classes, procurement levels, manufacturing origins and administration routes. Descriptive and statistical analyses were performed to explore the relationship between consumption, price and bidding mechanisms. Results: The total consumption of cancer medications between 2019 and 2023 in Vietnam was estimated to be about $1.4 billion. Of which the number slightly increased in 2020 before dropping sharply to 2022 and finally rebounding and reaching its peak in 2023 with $359.5 million. Targeted therapies consistently accounted for the largest proportion (44-48%), followed by chemotherapies with 34-39% and immunotherapies with 8-16%. Most expenditures were attributed to originator products and high-quality generics (Group 1), contributing 73-85% annually. Overall, the mean price per milligram decreased over time, with notable variation driven by shifts in the distribution of bidding technical groups while the centralized national-bidding was generally more efficient than regional procurements. Conclusion: Cancer medication consumption in Vietnam fluctuated substantially between 2019 and 2023, accompanied by significant changes in procurement patterns and the pandemic. Strengthened and targeted policies are required to optimize the economic impact of this group of medication, while broader efforts are needed to alleviate the cancer burden in Vietnam.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.